Bot Image, Inc. develops ProstatID™, an FDA-cleared AI software that enhances the interpretation of prostate MRI scans by automatically detecting and diagnosing cancerous lesions in real-time. This technology addresses the challenges of time-consuming and complex MRI readings, significantly improving diagnostic accuracy and treatment planning for prostate cancer.
Funding
$2.9M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Interpreting prostate MRI scans is challenging and time-consuming due to the complexity of the images and the need to differentiate cancerous lesions from other conditions. Historically, the accuracy of radiological interpretation of prostate MRI has been inconsistent, leading to a lack of confidence in prostate diagnostics.
Solution
Bot Image, Inc. offers ProstatID™, an FDA-cleared AI software designed to enhance the interpretation of prostate MRI scans, improving diagnostic accuracy and treatment planning for prostate cancer. ProstatID™ automatically detects and diagnoses cancerous lesions in real-time, providing physicians with a comprehensive view of the entire prostate. The software is trained on a large dataset of biopsied cases, enabling it to differentiate cancer from benign conditions, and its results are returned in under 5 minutes. ProstatID™ is available as a SaaS medical device, connecting directly from the hospital or imaging center PACS system to Bot Image™’s cloud server, ensuring cyber-secure and HIPAA-compliant operation.
Target Audience
The primary users are radiologists, urologists, and interventionalists involved in prostate cancer screening, detection, diagnosis, and treatment planning.
Features
- AI-driven detection and diagnosis of cancerous lesions on prostate MRI scans
- Real-time results, typically under 5 minutes
- Color-overlayed T2W images indicating segmented lesions with individual cancer risk scores
- Trained on over 1000 biopsied cases with over 6000 biopsy points
- Cyber-secure and HIPAA-compliant SaaS deployment
- Seamless integration with existing PACS systems
- No additional equipment or physician effort required
- 3D views of high-risk lesions within a transparent rendition of the prostate gland for interventional targeting